Adam Taich - 09 Sep 2026 Form 4 Insider Report for 10x Genomics, Inc. (TXG)

Reporting relationship: Chief Financial Officer
Issuer ticker: TXG
Reported as of: 09 Sep 2026
Net transaction value: -$2,995,470
SEC form: 4
Accepted by SEC: 11 Sep 2026, 16:47:39 UTC
Prior SEC filing: 26 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Randy Wu, as Attorney-in-Fact for Adam Taich

Key filing fact

Adam Taich filed Form 4 for 10x Genomics, Inc. (TXG) on 11 Sep 2026.

Key facts

This page summarizes Adam Taich's Form 4 filing for 10x Genomics, Inc. (TXG).
3 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 11 Sep 2026, 16:47.

Change

Previous filing in this sequence was filed on 26 Aug 2026.
Current net transaction value: -$2,995,470.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001971187 Primary reporting owner

Taich Adam

Relationship: Chief Financial Officer
Address: 10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON
Signature: /s/ Randy Wu, as Attorney-in-Fact for Adam Taich
Signature date: 11 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TXG transaction

Class A Common Stock

Sale

Transaction value: $76,795
Shares: -1,206
Change %: -0.33%
Price: $63.68
Shares after: 361,526
Date: 09 Sep 2026
Ownership: Direct
Footnotes: F1, F2

TXG transaction

Class A Common Stock

Sale

Transaction value: $2,021,125
Shares: -31,428
Change %: -8.7%
Price: $64.31
Shares after: 330,098
Date: 09 Sep 2026
Ownership: Direct
Footnotes: F1, F3

TXG transaction

Class A Common Stock

Sale

Transaction value: $897,550
Shares: -13,754
Change %: -4.2%
Price: $65.26
Shares after: 316,344
Date: 09 Sep 2026
Ownership: Direct
Footnotes: F1, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on June 10, 2026.

Footnote F2

This transaction was executed in multiple trades at prices ranging from $63.67 to $63.83, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Footnote F3

This transaction was executed in multiple trades at prices ranging from $64.01 to $64.87, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Footnote F4

This transaction was executed in multiple trades at prices ranging from $64.88 to $65.875, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.